
Organovo Holdings Cash Flow 2026-2008 | ONVO
Brief overview of Organovo Holdings's cash flow quality
The comparison covers five available annual reports between 2020 and 2025.
Operating cash flow is negative at -$9.5 million, leaving internal funding capacity weak.
Positive operating cash flow appeared only 0 times out of five; a stable cash profile has not formed.
Overall assessment
Organovo Holdings's cash flows remain vulnerable. Negative or unstable generation materially reduces financial flexibility.
Annual Cash Flow Organovo Holdings
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-10.8 M | -9.46 M | -14.7 M | -12.4 M | -8.45 M | -13.3 M | -14.9 M | -20.4 M | -28.9 M | - | - | - | -15.6 M | - | -9.69 M | -1.91 M | -820 K | - | - |
Depreciation & Amortization |
215 K | 266 K | 280 K | 293 K | 142 K | 41 K | 1.14 M | 980 K | 1.27 M | 1.15 M | 815 K | 472 K | 387 K | - | 195 K | 68 K | 59 K | - | - |
Accounts Payables |
1.02 M | 1.64 M | 627 K | 331 K | 415 K | 281 K | 720 K | 628 K | 464 K | 1.17 M | 787 K | 1.39 M | 326 K | 641 K | 425 K | 658 K | - | - | - |
Accounts Receivables |
32 K | 30 K | 33 K | 152 K | - | - | 111 K | 503 K | 883 K | 647 K | 259 K | - | - | - | - | - | - | - | - |
Total Inventories |
- | - | 297 K | - | - | - | - | 490 K | 842 K | 550 K | 334 K | 66 K | 63 K | 88 K | 360 K | 292 K | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Organovo Holdings
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | -3.94 M | - | - | - | -2.98 M | - | - | - | -5.31 M | - | - | -7.68 M | -2.41 M | - | - | -6.91 M | -3.56 M | - | - | -11.2 M | -9.72 M | -2.57 M | - | -11.7 M | -11.1 M | -5.94 M | - | -15.3 M | -11.3 M | - | - | - | -10.7 M | - | - | - | - | - | - | - | - | - | - | - | 3.4 M | - | - | - | -2.66 M | -2.76 M | - | -6.14 M | -4.16 M | -3.56 M | - | -647 | -10.5 K | -140 K |
Depreciation & Amortization |
- | - | 61 K | - | - | - | 70 K | - | - | - | 67 K | - | - | 234 K | 50 K | - | - | 96 K | 59 K | - | - | 18 K | 8 K | 4 K | - | 1.14 M | 379 K | 205 K | - | 824 K | 570 K | - | - | - | 326 K | - | - | 824 K | 502 K | - | - | 560 K | 324 K | - | - | 334 K | 208 K | - | - | 288 K | 190 K | 80 K | - | 178 K | 100 K | 17 K | - | 49.9 K | 32.4 K | 15.6 K |
Accounts Payables |
671 K | 580 K | 673 K | 1.64 M | 930 K | 419 K | 1.12 M | 627 K | 471 K | 435 K | 488 K | 331 K | 242 K | 441 K | 130 K | 415 K | 605 K | 958 K | 577 K | 281 K | 411 K | 201 K | 110 K | 720 K | 822 K | 152 K | 553 K | 628 K | 647 K | 449 K | 396 K | 464 K | 452 K | 477 K | 558 K | 1.17 M | 722 K | 754 K | 481 K | 787 K | 466 K | 567 K | 1.03 M | 1.39 M | 495 K | 530 K | 839 K | 326 K | 311 K | 477 K | 374 K | 641 K | 425 K | 61.3 K | 260 K | 441 K | 658 K | 658 K | 658 K | 658 K |
Accounts Receivables |
33 K | 32 K | 32 K | 30 K | 26 K | 29 K | 48 K | 33 K | 33 K | 55 K | 149 K | 152 K | 76 K | - | - | - | - | - | - | - | - | 19 K | 84 K | 111 K | 165 K | 619 K | 538 K | 503 K | 547 K | 475 K | 628 K | 883 K | 1.17 M | 1.03 M | 772 K | 647 K | 1.03 M | 606 K | 103 K | 259 K | 165 K | 180 K | 132 K | - | - | 30 K | 60 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
- | - | - | - | - | 640 K | 408 K | 297 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 351 K | 506 K | 490 K | 1.05 M | 1.04 M | 1.04 M | 842 K | 605 K | 496 K | 461 K | 550 K | 328 K | 445 K | 512 K | 334 K | 71 K | 68 K | 69 K | 66 K | 69 K | 70 K | 71 K | 63 K | 82 K | 74 K | 85 K | 88 K | 360 K | 312 K | 527 K | 337 K | 292 K | 292 K | 292 K | 292 K |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Organovo Holdings, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Diagnostics research sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | ||
|
Neogen Corporation
NEOG
|
$ 9.4 | 2.29 % | $ 2.04 B | ||
|
Natera
NTRA
|
$ 253.82 | 0.63 % | $ 34.7 B | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Celcuity
CELC
|
$ 83.26 | 0.97 % | $ 3.89 B | ||
|
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Koninklijke Philips N.V.
PHG
|
$ 26.1 | 2.19 % | $ 24.7 B | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
Personalis
PSNL
|
$ 11.73 | -1.26 % | $ 1.05 B | ||
|
Co-Diagnostics
CODX
|
$ 1.51 | 7.09 % | $ 2.01 M | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
- | - | $ 9.42 M | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B | ||
|
Neuronetics
STIM
|
$ 1.82 | -2.67 % | $ 120 M | ||
|
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | ||
|
Exact Sciences Corporation
EXAS
|
- | - | $ 19.8 B | ||
|
CareDx, Inc
CDNA
|
$ 35.41 | -0.95 % | $ 1.89 B | ||
|
NeoGenomics
NEO
|
$ 15.27 | 13.96 % | $ 1.96 B | ||
|
QIAGEN N.V.
QGEN
|
- | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
- | - | $ 2.69 B | ||
|
Waters Corporation
WAT
|
$ 379.48 | -1.15 % | $ 22.6 B | ||
|
Medpace Holdings
MEDP
|
$ 584.93 | 2.44 % | $ 16.9 B | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 235.22 | -0.31 % | $ 26.1 B | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | ||
|
Exagen
XGN
|
$ 4.35 | -2.25 % | $ 93.8 M | ||
|
Biomerica
BMRA
|
$ 1.59 | -0.62 % | $ 3.65 M | ||
|
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | ||
|
DarioHealth Corp.
DRIO
|
$ 7.1 | -5.27 % | $ 28.3 M | ||
|
OpGen
OPGN
|
- | -16.95 % | $ 1.54 M | ||
|
Anixa Biosciences
ANIX
|
$ 3.48 | -1.14 % | $ 113 K | ||
|
PerkinElmer
PKI
|
- | -0.91 % | $ 14.7 B | ||
|
DexCom
DXCM
|
$ 75.14 | 0.39 % | $ 29.3 B | ||
|
OPKO Health
OPK
|
$ 1.37 | -17.27 % | $ 1.03 B | ||
|
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | ||
|
ICON Public Limited Company
ICLR
|
$ 178.18 | -1.14 % | $ 14 B | ||
|
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | ||
|
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | ||
|
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M | ||
|
Syneos Health
SYNH
|
- | - | $ 4.46 B |